IL28B Polymorphisms as a Pretreatment Predictor of Response to HCV Treatment
- 1 December 2012
- journal article
- review article
- Published by Elsevier in Infectious Disease Clinics of North America
- Vol. 26 (4) , 863-877
Abstract
No abstract availableKeywords
This publication has 104 references indexed in Scilit:
- An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver DiseasesHepatology, 2011
- IL28BPolymorphism Does Not Determine Outcomes of Hepatitis B Virus or HIV InfectionThe Journal of Infectious Diseases, 2010
- Genetic Variation in IL28B Is Associated With Chronic Hepatitis C and Treatment Failure: A Genome-Wide Association StudyGastroenterology, 2010
- Genetic variation in IL28B and spontaneous clearance of hepatitis C virusNature, 2009
- Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis CNature Genetics, 2009
- IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapyNature Genetics, 2009
- Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearanceNature, 2009
- Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C InfectionNew England Journal of Medicine, 2009
- How to Interpret a Genome-wide Association StudyJAMA, 2008
- Epidemiology of hepatitis C virus infectionWorld Journal of Gastroenterology, 2007